Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00947882 · ClinicalTrials.gov registry record · Phase 2
A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 404
- Enrollment target
NCT00947882 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 404 participants.
The verdict
NCT00947882, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 404 participants
- Enrollment target
Study Summary
A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)
Interventions
- DRUG Placebo
- DRUG Degarelix 10 mg
- DRUG Degarelix 20 mg
- DRUG Degarelix 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00947882
The ClinicalTrials.gov registry entry for NCT00947882 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 404 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00947882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00947882 about?
NCT00947882 is a clinical study titled "A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)". A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)
What is the current status of trial NCT00947882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 404 participants. The study started on 2009-08. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00947882?
The interventions under investigation include: Placebo (DRUG), Degarelix 10 mg (DRUG), Degarelix 20 mg (DRUG), Degarelix 30 mg (DRUG).
Who is sponsoring clinical trial NCT00947882?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.